placebo

Org: Gustave Roussy Cancer Center, Université Paris Saclay, Paris, France, Royal Free London NHS Foundation Trust, UCL Division of Surgery and Interventional Science,

Abstract

Plasma mutational burden in PIK3CA and TP53 independently predicts early progression in patients with HR+/HER2- metastatic breast cancer (MBC) enrolled in the GEICAM/2014-12 FLIPPER trial.

Org: Sysmex Inostics Gmbh, Sysmex Inostics, Inc., GEICAM Spanish Breast Cancer Group, Cancer Trials Ireland, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) ,

Abstract

Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy.

Org: Mayo Clinic Department of Radiation Oncology, Rochester, MN, Mayo Clinic, Phoenix, AZ, Division of Hematology & Medical Oncology,

Abstract

A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study.

Org: Department of Medicine, University of Chicago, Johns Hopkins Medicine, University of Pennsylvania, Emory University Winship Cancer Institute, Hollings Cancer Center,

Abstract

On-treatment (tx) dynamic circulating tumor DNA changes (∆ctDNA) associated with progression-free survival (PFS) and overall survival (OS) of patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA-3 (ML-3).

Org: BC Cancer - Vancouver Centre, Novartis Pharmaceuticals Corporation, Novartis Institutes for BioMedical Research, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori Regina Elena,

Abstract

Use of liquid biomarker thymidine kinase activity (TKa) to predict outcome and progression in patients with metastatic breast cancer (MBC) in the GEICAM/2014-12 FLIPPER trial.

Org: Hospital del Mar, Barcelona, Spain, CIBERONC-ISCIII, Biovica International AB, Hospital Clínico Universitario de Valencia, INCLIVA-Biomedical Research Institute,

Abstract

EMBARK post hoc analysis of sexual activity (SA) patient-reported outcomes (PROs) in patients (pts) who were sexually active or interested in sex at baseline (BL).

Org: Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Memorial Sloan Kettering Cancer Center, Vancouver Prostate Centre, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori,

Abstract

Post hoc analysis of progression-free survival (PFS) and overall survival (OS) by mechanism of mismatch repair (MMR) protein loss in patients with endometrial cancer (EC) treated with dostarlimab plus chemotherapy in the RUBY trial.

Org: AMITA Health Adventist Medical Center, Indiana University Health & Simon Cancer Center, Hungarian National Institute of Oncology, Soroka University Medical Center, OLV Hospital,

Abstract

Association between prostate-specific antigen (PSA) level <0.2 ng/mL and risk of radiological progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Follow-up analysis of ARAMIS.

Org: Divisions of Medical Oncology and Urology, Bayer Consumer Care AG,

Abstract

Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow-up.

Org: Maria Sklodowska-Curie National Cancer Research Institute,

Abstract

Efficacy and safety of nirogacestat in patients with desmoid tumor and adenomatous polyposis coli (APC) mutation: Phase 3 DeFi analyses.

Org: Stamford, CT,

Abstract

Impact of hepatitis B virus (HBV) infection on efficacy and safety in the KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC).

Org: Amsterdam UMC, University of Amsterdam, ENETS Center of Excellence, Cancer Center Amsterdam, Charite Campus Charite Mitte,

Abstract

Randomized double-blind placebo-controlled trial evaluating pregabalin for chronic cough in patients with lung cancer.

Org: Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, MS Ramaiah Memorial Hospital, Emeritus Professor, Tata Memorial Centre (TMC), Tata Memorial Hospital, Tata Memorial Centre,

Clinical trial

Exploring the Use of Remimazolam (BYFAVO®) in Patients at High Risk for ERCP to Reduce Intraoperative Hypotension and Assess Safety and Efficacy: A Randomized Controlled Trial

Status: Not yet recruiting, Estimated PCD: 2028-12-31

Abstract

EMBARK post hoc analysis of impact of treatment suspension (TxS) on health-related quality of life (HRQoL).

Org: IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy, Department of Urology and Research Program in Systems Oncology, University of Helsinki, and Helsinki University Hospital, Helsinki, Finland, Instituto Valenciano de Oncologia, Valencia, Spain, Astellas Pharma Inc., Northbrook, IL, Pfizer Inc., New York, NY,

Abstract

Physical activity and dexamethasone for cancer related fatigue: A preliminary placebo controlled randomized control trial.

Org: The University of Texas MD Anderson Cancer Center, Houston, TX, USA,

Abstract

Three-year follow-up data from KEYNOTE-966: Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC).

Org: Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Prince of Wales Hospital, Department of Clinical Oncology, The Chinese University of Hong Kong, Amsterdam UMC, University of Amsterdam, Department of Medical Oncology, ENETS Center of Excellence, Cancer Center Amsterdam, Gastroenterology, Hepatology, Infectious Diseases and Endocrinology Department, Hannover Medical School,

Abstract

Time course of adverse events in primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial.

Org: Department of Oncology, Odense University Hospital, Willis-Knighton Cancer Center, Gynecologic Oncology Associates, Department of Gynaecology, Obstetrics, and Neonatology, General University Hospital in Prague, Division of Gynecologic Oncology, McGill University Health Centre,

Abstract

Final safety results from ATHENA–MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer.

Org: GOG Foundation, National Cancer Center Korea, Hospital Universitario Virgen de Valme, Department of Cancer and Blood, Limited Liability Company MedPomosch,

Abstract

LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive (RET+) NSCLC.

Org: Chengdu Institute of Respiratory Health, Branch of National Clinical Research Center for Respiratory Disease, The Third People's Hospital of Chengdu, Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Klinik Floridsdorf,

Abstract

Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib + best supportive care (BSC) compared with placebo + BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial.

Org: Veneto Institute of Oncology IOV-IRCCS Padua, Asklepios Tumorzentrum Hamburg, Takeda Pharma Vertrieb GmbH & Co. KG, HUTCHMED International Inc., University Hospitals Gasthuisberg / Leuven & KULeuven,

Abstract

Effect of low-dose tamoxifen on IGF-I/IGFBP-3 and estradiol/SHBG ratio and their prognostic/predictive effect in DCIS/LCIS/ADH.

Org: E.O. Ospedali Galliera, Azienda Ospedaliera-Universitaria Città della Salute e della Scienza, ASL AL Piemonte, Oncologia Medica - Ospedale San Bortolo Azienda ULSS8 Berica, Romagna Local Health Authority,

Clinical trial

Novel Approach for Oligospermia (NAPO): A Randomized Controlled Trial

Status: Not yet recruiting, Estimated PCD: 2024-12-01

Abstract

Monitoring ovarian function in oncology studies: Results and insights from the DeFi phase 3 study of nirogacestat in desmoid tumor.

Org: Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, University of Washington and Fred Hutchinson Cancer Research Centre, University of Michigan, Rogel Comprehensive Cancer Center,

Clinical trial

Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Migraine

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

Impact of Postoperative Skin Disinfection With Chlorhexidine on Bacterial Colonization Following Shoulder Arthroplasty Surgery: A Controlled Randomized Study

Status: Completed, Estimated PCD: 2023-03-20

Clinical trial

A Randomised, Placebo-controlled Trial of Oral Nitazoxanide for the Empiric Treatment of Acute Gastroenteritis Among Australian Indigenous Children

Status: Terminated, Estimated PCD: 2021-04-21

Clinical trial

The Effectiveness of Hydroxylated Polymethoxy Flavones Solid Dispersion Incorporated Sodium Carboxymethyl Cellulose Gel With Periodontal Debridement in the Treatment of Periodontitis. Clinical- Biochemical Study

Status: Not yet recruiting, Estimated PCD: 2023-11-20

Clinical trial

Risks for Transition From Therapeutic Hypnotic Use to Abuse

Status: Completed, Estimated PCD: 2022-02-22

Clinical trial

Prazosin and CSF Biomarkers in mTBI

Status: Terminated, Estimated PCD: 2023-01-03

Clinical trial

Treating Early Stage Diabetic Retinopathy

Status: , Estimated PCD: 2027-12-31

Clinical trial

Randomized Trial of Adjuvant Curcumin After Prostatectomy

Status: Recruiting, Estimated PCD: 2025-06-01

Clinical trial

Cannabidiol as an Adjunctive to Prolonged Exposure for the Treatment of PTSD

Status: Recruiting, Estimated PCD: 2024-09-30

Clinical trial

Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP): a Randomized Double Blind Placebo Controlled Phase II Study

Status: Recruiting, Estimated PCD: 2024-10-15

Clinical trial

Evaluation of the Efficacy of Suprascapular Nerve Block in Adhesive Capsulitis: a Randomized Controlled Superiority Trial

Status: Not yet recruiting, Estimated PCD: 2024-11-01

Clinical trial

Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients; Double-blinded Randomized Controlled Trial

Status: Not yet recruiting, Estimated PCD: 2025-09-01

Clinical trial

Clinical Study of Ginkgo Biloba Ketone Ester Tablets in Diabetes Related Dementia

Status: Not yet recruiting, Estimated PCD: 2026-06-30

Clinical trial

A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy, Pharmacokinetics and Safety of Remibrutinib (LOU064) for 24 Weeks in Adolescents From 12 to Less Than 18 Years of Age With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Followed by an Optional Open-label Extension for up to Another 3 Years and an Optional Safety Long-term Treatment-free Follow-up Period for up to an Additional 3 Years

Status: Recruiting, Estimated PCD: 2025-11-21

Clinical trial

The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 (FGF23 ) in Chronic Kidney Disease

Status: Completed, Estimated PCD: 2012-05-01

Clinical trial

Effects of Intravascular Administration of Mesenchymal Stromal Cells Derived From Wharton's Jelly of the Umbilical Cord on Systemic Immunomodulation and Neuroinflammation After Traumatic Brain Injury.

Status: Not yet recruiting, Estimated PCD: 2026-12-31

Clinical trial

Leukine (Sargramostim) for Parkinson's Disease

Status: Completed, Estimated PCD: 2016-01-01

Clinical trial

Molecular Mechanisms of Antipsychotic-induced Insulin Resistance in Healthy Volunteers

Status: Completed, Estimated PCD: 2023-10-01

Clinical trial

Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache

Status: Recruiting, Estimated PCD: 2025-09-01

Clinical trial

Chronic Postconcussive Headache: A Placebo-Controlled Treatment Trial of Prazosin

Status: Completed, Estimated PCD: 2023-05-31

Clinical trial

Dexmedetomidine Compared With Ondansetron in Treating Postanesthetic Shivering in Patients After Regional Anesthesia for Cesarean Section-a Randomized Clinical Trial.

Status: Completed, Estimated PCD: 2021-09-05

Clinical trial

Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy

Status: Not yet recruiting, Estimated PCD: 2028-10-01

Clinical trial

The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome in Breast Cancer Patients: A Multicenter, Phase III, Randomized, Double-blind, Controlled Trial

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

Single Blind Randomized Controlled Trial to Assess the Safety and Efficacy of High Dose Pulse Intravenous Corticosteroid Therapy to Treat Patients With Complicated/Fulminant Acute Myocarditis

Status: Recruiting, Estimated PCD: 2028-03-01

Clinical trial

COCOA Flavanols to Improve Walking Performance in PAD: the COCOA-PAD II Trial

Status: Recruiting, Estimated PCD: 2026-05-31

Clinical trial

Effects of Open-label vs Double-blind Treatment in IBS.

Status: Completed, Estimated PCD: 2019-01-01

Clinical trial

The Effect of Intraoperative Dexmedetomidine on Postoperative Morphine Requirements and Oral Intake After Breast Cancer Surgery

Status: Recruiting, Estimated PCD: 2024-07-01

Clinical trial

A Phase-1, Open-Label, Placebo-Controlled Evaluation of a Live, Recombinant Newcastle Disease Virus Expressing the Spike Protein of SARS-CoV-2 (NDV-HXP-S), an Investigational Product for Intranasal (IN) and/or Intramuscular (IM) Vaccination in Healthy Adults Previously Immunized Against COVID-19.

Status: Active (not recruiting), Estimated PCD: 2023-05-03

Clinical trial

Dynamic-Contrast Enhanced MRI Pharmacodynamic Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma

Status: Completed, Estimated PCD: 2007-01-01

Clinical trial

TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation

Status: Completed, Estimated PCD: 2020-12-01

Clinical trial

Intermittent Vitamin D Administration in the Nursing Home: Impact on Vitamin D Status, Falls, Bone Turnover and Bone Density

Status: Completed, Estimated PCD: 2004-05-01

Clinical trial

Effect of Androgel on Atherogenesis, Inflammation, Cardiovascular Risk Factors And Adiposity in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism.: a Prospective, Randomized and Controlled-Study

Status: Terminated, Estimated PCD: 2018-03-01

Clinical trial

Metformin BenefIts Lower Extremities With Intermittent Claudication (MOBILE_IC)

Status: Recruiting, Estimated PCD: 2026-02-28

Clinical trial

Zoledronate Early to Hip Fracture Patients - Safe and Effective? A Double-blinded Randomized Controlled Treatment Strategy Trial on Zoledronate in Hip Fracture Patients

Status: Recruiting, Estimated PCD: 2026-03-31

Clinical trial

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Status: Active (not recruiting), Estimated PCD: 2022-09-09

Clinical trial

Pain Relieving Potentials of Preoperative Combination of Single Dose Oral Duloxetine and Intravenous Magnesium Sulphate in Acute and Chronic Post Mastectomy Pain: A Randomized Controlled Trial

Status: Recruiting, Estimated PCD: 2024-04-01

Clinical trial

A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction With Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer

Status: , Estimated PCD: 2025-02-25

Clinical trial

Randomized Placebo-controlled Phase III Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up

Status: Active (not recruiting), Estimated PCD: 2022-12-31

Clinical trial

Radiographic and Clinical Assessment of Locally Delivered Camel Whey Protein Gel and Camel Whey Protein Nanoparticles Gel in Stage II Grade B Periodontitis: Randomized Controlled Clinical Trial.

Status: Recruiting, Estimated PCD: 2024-11-15

Clinical trial

DUPECZEMAIN : Double Blind Placebo-controlled Randomized Multicenter Study Assessing the Efficacy and Safety of Dupilumab in Moderate to Severe Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids

Status: Recruiting, Estimated PCD: 2024-01-01

Clinical trial

How Does the Brain Learn About Positive and Negative Things?

Status: Completed, Estimated PCD: 2023-04-30

Clinical trial

A Safe Ketamine-Based Therapy for Treatment Resistant Depression

Status: Completed, Estimated PCD: 2014-06-06

Clinical trial

Effectiveness of Iron Sucrose Combined With rHuEPO and Ascorbic Acid in Improving Perioperative Anaemia in Patients Undergoing Major Cardiac Surgery

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

Efficacy of Nasal Oxygen Therapy to Reduce Postoperative Complications in Ankle Trauma Surgery in At-risk Patients: a Randomized Pilot Study

Status: Recruiting, Estimated PCD: 2024-07-01

Clinical trial

Berberine Effects on Clinical Symptoms and Metabolic Disturbance as an Adjunctive Therapy in Patients With Schizophrenia: a Randomized Double-blind Placebo-controlled Study

Status: Completed, Estimated PCD: 2015-12-14

Clinical trial

The Analgesic Efficacy of Erector Spinae Plane Block in Ankle and Foot Surgery: A Randomized Controlled Study

Status: Completed, Estimated PCD: 2023-08-15

Clinical trial

A Study of Two Different Treatment Strategies in IgG4-related Disease Patients With Re-elevation of Serum IgG4 Level During Maintenance Remission Period: a Randomized Double Blind Placebo Controlled Multicenter Study

Status: Not yet recruiting, Estimated PCD: 2025-12-01

Clinical trial

A Prospective Feasibility Trail to Compare the Efficacy of Intermittent Surface Oxygenation With Continuous Surface Oxygenation During Hypothermic Machine Perfusion of Kidneys Donated After Circulatory Death

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2

Status: Recruiting, Estimated PCD: 2025-07-01

Clinical trial

The Effects of Statin and Angiotensin-converting Enzyme Inhibitor on Coronary Flow Reserve, indEx of Microcirculatory Resistance, and Symptoms in Patients With Spontaneous Coronary Artery Dissection (SAFER-SCAD) Study

Status: Terminated, Estimated PCD: 2019-09-13

Clinical trial

A Phase 2b, Randomized, Controlled Double-blind, Multicenter Study Comparing the Efficacy and Safety of Zetomipzomib (KZR-616) 30 mg or 60 mg With Placebo in Patients With Active Lupus Nephritis

Status: Recruiting, Estimated PCD: 2026-05-01

Clinical trial

Use of Omalizumab Will Increase the Pregnancy Rate, Proof of Concept Study, Where Women With Asthma and Infertility Will be Treated Three Times With Weight and IgE Balanced Dosis at the First Day of Their Period Bleeding

Status: Active (not recruiting), Estimated PCD: 2023-12-31

Clinical trial

A Multicenter, Double-blind, Placebo-randomized Controlled Clinical Study on the Treatment of Non-alcoholic Steatohepatitis With Tibetan Drug Langqing Atar

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

Phase 2b Randomized Double-blind, Placebo-controlled Trial to Estimate the Potential Efficacy and Safety of Two Repurposed Drugs, Acetylsalicylic Acid and Ibuprofen, for Use as Adjunct Therapy Added to, and Compared With, the Standard WHO-recommended TB Regimen (SMA-TB)

Status: Recruiting, Estimated PCD: 2024-10-01

Clinical trial

Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: TOBRA - A Multicenter Randomized Controlled Trial

Status: Recruiting, Estimated PCD: 2025-03-31

Clinical trial

Topical Chemoprevention of Skin Cancer Biomarkers

Status: Active (not recruiting), Estimated PCD: 2023-12-01

Clinical trial

The Acute Effect of Inflammatory Markers of Atherosclerotic Plaque in Humans

Status: Completed, Estimated PCD: 2006-03-01

Clinical trial

Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum

Status: Completed, Estimated PCD: 2015-05-01

Clinical trial

Ketamine and Morphine Versus Morphine Alone for the Treatment of Acute Pain in the Emergency Department

Status: Terminated, Estimated PCD: 2014-04-01

Clinical trial

Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) (ABROGATE)

Status: Active (not recruiting), Estimated PCD: 2023-07-25

Clinical trial

Clinical Study of Vitamin B5 in Adjuvant Treatment of Inflammatory Bowel Disease

Status: Recruiting, Estimated PCD: 2024-02-01

Clinical trial

Intra-nodal Injection of Gentamicin for the Treatment of Suppurated Cat Scratch Disease's Lymphadenitis: A Randomized Controlled Study

Status: Recruiting, Estimated PCD: 2023-12-01

Clinical trial

Prophylactic Frequent Premature Ventricular complexeS sUPPression on Left ventriculaR Function impairmEnt in aSymptomatic patientS

Status: Not yet recruiting, Estimated PCD: 2027-06-01

Clinical trial

Safety and Efficacy of the Stomach Ulcer Drug Polaprezinc (POL) on Enzalutamide- or Abiraterone-resistant CRPC

Status: Completed, Estimated PCD: 2023-01-20

Clinical trial

Vitamin D Supplementation Requirement in Obese Subjects

Status: Terminated, Estimated PCD: 2013-08-01

Clinical trial

A Randomized Trial to Determine if Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Treated With Capecitabine Chemotherapy

Status: Terminated, Estimated PCD: 2009-03-18

Clinical trial

Evaluation of Glucocorticoids Plus Rituximab Compared to Glucocorticoids Plus Placebo for the Treatment of Patients With Newly-Diagnosed or Relapsing IgA Vasculitis: A Prospective, Randomized, Controlled, Double-blind Study

Status: Recruiting, Estimated PCD: 2025-03-11

Clinical trial

A Randomized Multicentre, Double-Blinded and Placebo-Controlled, Trial of Human Albumin in the Treatment of Decompensated Cirrhosis Guided by the MICROB-PREDICT Biomarker

Status: Recruiting, Estimated PCD: 2025-03-01

Clinical trial

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Efficacy of Thalidomide for Refractory Small Intestinal Bleeding From Vascular Malformation

Status: Completed, Estimated PCD: 2020-12-01

Clinical trial

Glucocorticoids Associated With Antihistamines Versus Antihistamines Randomized Double Blinded for the Management of Acute Urticaria in Emergency

Status: Completed, Estimated PCD: 2014-02-01

Clinical trial

Multicenter, Randomised, Placebo-controlled, Double Blinded, Parallel Arm Proof-of-concept Trial of Lixisenatide in Patients With Early Parkinson's Disease

Status: Completed, Estimated PCD: 2021-04-15

Clinical trial

Physiotherapy Intervention in Patients With Persistent COVID-19 Disease Using Aerobic Exercise and Association With Genetics

Status: Completed, Estimated PCD: 2022-07-01

Clinical trial

The Effect of Mild Sedation and Analgesia on Radial Artery Cannulation in Novice Operators

Status: Recruiting, Estimated PCD: 2024-06-01

Clinical trial

Can Vitamin D Supplementation Prevent Food Allergy in Infants? The VITALITY Trial

Status: Active (not recruiting), Estimated PCD: 2028-04-01

Clinical trial

The Effect of Ultrasound-guided Erector Spinae Plane Block on Postoperative Analgesia in Radiofrequency Ablation Therapy

Status: Completed, Estimated PCD: 2023-01-18

Clinical trial

Effect of Remimazolam on Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Cholecystectomy

Status: Recruiting, Estimated PCD: 2024-04-12

Clinical trial

" Ilomedin for Treatment of Septic Shock With Persistent Microperfusion Defects ", a Double-blind, Randomized Controlled Trial:The I-MICRO Trial

Status: Completed, Estimated PCD: 2024-01-18

Clinical trial

A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients Presenting to the Emergency Department and to Evaluate Its Side Effect and Safety Profile When Used in This Clinical Situation.

Status: Terminated, Estimated PCD: 2009-11-01

Clinical trial

Phase I Clinical Study on the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Food Effects of Single and Multiple Oral HRS-5346 Tablets in Healthy Subjects

Status: Not yet recruiting, Estimated PCD: 2024-12-01

Clinical trial

Randomized, Double-Blind, Placebo-Controlled Study of Effects of Combined Spinal Epidural Analgesia on Intrapartum Fever.

Status: Withdrawn, Estimated PCD: 2010-06-01

Clinical trial

GnRH for Luteal Support in IVF/ICSI/FET Cycles

Status: Recruiting, Estimated PCD: 2025-03-01

Clinical trial

Clinical and Radiographic Evaluation of Melatonin and Metformin Loaded Nanoparticles in the Treatment of Periodontal Intra-bony Defects: A Randomized Controlled Clinical Trial

Status: , Estimated PCD: 2024-05-01

Clinical trial

Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction - PRESENT HF Study

Status: Recruiting, Estimated PCD: 2025-02-01

Clinical trial

Should We Use Oral Valacyclovir in Acute Herpetic Gingivostomatitis in Children? A Randomized Controlled Trial

Status: Completed, Estimated PCD: 2022-12-01

Clinical trial

A Multicentre Randomized Controlled Clinical Study on the Chitosan Nanocrystalline Qinteng Huoxue Runji Ointment Therapy for Psoriasis With Blood Stasis Syndrome.

Status: Not yet recruiting, Estimated PCD: 2026-06-01

Clinical trial

A Pilot Study of Atorvastatin on Prevention of Metabolic Syndrome in Subjects With Prostate Cancer on Long Term Androgen-deprivation Therapy

Status: Withdrawn, Estimated PCD: 2013-02-01

Clinical trial

Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial

Status: Active (not recruiting), Estimated PCD: 2018-06-01

Clinical trial

Topiramate Treatment of Alcohol Use Disorder in African Americans

Status: Terminated, Estimated PCD: 2021-12-31

Clinical trial

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)

Status: Recruiting, Estimated PCD: 2023-06-29

Clinical trial

Effect of Physiotherapy on the Usage of Proton Pump Inhibitors and Changes in the Pressure of the Lower Esophageal Sphincter in Patients With Achalasia After Per Oral Endoscopic Myotomy

Status: Recruiting, Estimated PCD: 2024-08-18

Clinical trial

Randomized Cross-over Trial of Sodium Bicarbonate on Muscle Mitochondrial Energetics and Physical Endurance in Chronic Kidney Disease and Metabolic Acidosis

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

Effect of Neflamapimod (VX-745) on Brain Inflammation Using Positron Emission Tomography (PET) Scan in Alzheimer's Disease (AD) Patients

Status: Completed, Estimated PCD: 2021-04-30

Clinical trial

Cell-Based Therapy in Rheumatoid Arthritis: Proof of Concept Phase 1 Trial

Status: Terminated, Estimated PCD: 2023-04-30

Clinical trial

A Phase II Study of the Anti-PDL1 Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid to Investigate Safety and Efficacy of This Combination in Recurrent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma

Status: Completed, Estimated PCD: 2021-06-01

Clinical trial

Effect of Rimonabant, a Cannabinoid Receptor 1 Antagonist on Weight Gain and Body Composition in Adults With Prader Willi Syndrome.

Status: Terminated, Estimated PCD: 2009-01-01

Clinical trial

Ziprasidone vs Placebo in the Prevention of Psychosis Among Symptomatic Adolescents and Young Adults at Prodromal Risk

Status: Completed, Estimated PCD: 2012-11-01

Clinical trial

The Effect of Local Intraoperative Steroid Administration on Post-ACDF Dysphagia - A Prospective Double-Blinded Study by High Resolution Impedance Manometry

Status: Completed, Estimated PCD: 2022-09-20

Clinical trial

Multicenter, Randomized, Double-blind Placebo Controlled Trial of Bezafibrate for the Treatment of Primary Biliary Cirrhosis in Patients With Incomplete Response to Ursodesoxycholic Acid Therapy.

Status: Completed, Estimated PCD: 2016-12-31

Clinical trial

Effect of Probiotics Supplementation on the Side Effects of Radiation Therapy on the Immune System Among Colorectal Cancer Patients

Status: Withdrawn, Estimated PCD: 2022-09-30

Clinical trial

Comparison of the Efficacy of Gabapentin With Loratadine in the Treatment of Uremic Pruritus in Patients of Chronic Kidney Disease

Status: Completed, Estimated PCD: 2022-10-31

Clinical trial

Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old. A Multi-center Comparative Randomized Double-blind and Placebo-controlled Clinical Trial

Status: Terminated, Estimated PCD: 2015-03-01

Clinical trial

A Phase 1/2a Exploratory Clinical Trial to Evaluate the Safety of Oral Deferiprone (14 Days) Including Its Effect on Decreasing the Content of Iron in Subjects With Aneurysmal Subarachnoid Hemorrhage (aSAH) sIRB

Status: Active (not recruiting), Estimated PCD: 2023-12-21

Clinical trial

Study of the Cardio Renal Effects of SGLT2 Inhibitors Among Diabetic and Non-diabetic Lupus Nephritis Patients

Status: Active (not recruiting), Estimated PCD: 2023-10-01

Clinical trial

RATNO (Reducing Antibiotic Tolerance Using NO) Reducing Antibiotic Tolerance Using Low Dose Nitric Oxide in Cystic Fibrosis - a Phase 2 Pilot Study

Status: Completed, Estimated PCD: 2012-12-01

Clinical trial

Prazosin Augmentation of Outpatient Treatment of Alcohol Use Disorders in Active Duty Soldiers With and Without PTSD

Status: Completed, Estimated PCD: 2018-09-20

Clinical trial

Ghrelin Regulation and Structure: Effect of Thiazolidinedione Therapy on Ghrelin

Status: Terminated, Estimated PCD: 2011-05-01

Clinical trial

Nitrous Oxide for Posttraumatic Stress Disorder (PTSD): A Phase IIa Trial

Status: Terminated, Estimated PCD: 2022-08-31

Clinical trial

Effect of Vascepa on Progression of Coronary Atherosclerosis in Persons With Elevated Triglycerides (200-499) on Statin Therapy

Status: Completed, Estimated PCD: 2020-05-15

Clinical trial

Optimal FiO2 Value, Oxygen Reserve Index, and Prevention of Hyperoxemia in Children: A Prospective, Randomized, Single-blind Study

Status: Completed, Estimated PCD: 2022-09-30

Clinical trial

SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Diabetic and Non- Diabetic Lupus Nephritis Patients

Status: Active (not recruiting), Estimated PCD: 2023-10-08

Clinical trial

Phase 2 Study of Omalizumab in Oral Peanut Desensitization

Status: Completed, Estimated PCD: 2015-10-01

Clinical trial

The Effect of Botulinum Toxin A in Patients With Myofascial Pain Dysfunction Syndrome With and Without Zinc Supplementation (Randomized Controlled Trial)

Status: , Estimated PCD: 2023-04-20

Clinical trial

The Use of Ketorolac in Surgical Neonates

Status: Completed, Estimated PCD: 2018-12-31

Clinical trial

Evaluating Bronchodilator Response in Patients With Bronchiectasis

Status: Recruiting, Estimated PCD: 2024-04-01

Clinical trial

Intranasal Dexmedetomidine Decreases Emergence Delirium in Pediatric Patients After Sevoflurane Based General Anesthesia

Status: Terminated, Estimated PCD: 2013-03-01

Clinical trial

The Effect of Intravenous Iron Therapy and Erythropoiesis-stimulation Agent Combination on Renal Transplant Outcomes

Status: Not yet recruiting, Estimated PCD: 2026-05-01

Clinical trial

Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ)

Status: Recruiting, Estimated PCD: 2026-12-31

Clinical trial

Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)

Status: Completed, Estimated PCD: 2022-03-07

Clinical trial

GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration

Status: Completed, Estimated PCD: 2018-08-01

Clinical trial

A Prospective, Randomized, Double-blind, Multicenter Trial on the Effects of the Early Femoral Nerve Block in Elderly With Hip Fracture

Status: Recruiting, Estimated PCD: 2023-12-23

Clinical trial

The Impact of Low Flow Nocturnal Oxygen Therapy on Hospital Admissions and Mortality in Patients With Heart Failure and Central Sleep Apnea (LOFT-HF)

Status: Terminated, Estimated PCD: 2022-06-17

Clinical trial

PCSK9 Inhibition After Heart Transplantation

Status: , Estimated PCD: 2025-02-28

Clinical trial

Multicentre, Randomised, Double-blind, Placebo-controlled Trial of Nalmefene in Patients With Alcoholic Compensated Cirrhosis for the Treatment of Alcohol Dependence.

Status: Withdrawn, Estimated PCD: 2022-12-01

Clinical trial

Randomized Placebo Controlled Trial of Subcutaneous rhIL-1A (Anakinra) in the Management of Hospitalized Pediatric and Adult Patients With Macrophage Activation Syndrome

Status: Active (not recruiting), Estimated PCD: 2023-03-31

Clinical trial

Laboratory Models of Cocaine Self-administration

Status: Completed, Estimated PCD: 2016-06-01

Clinical trial

An 8-week, Placebo-controlled, Double-blind, Randomized, Fixed-dose Efficacy and Safety Trial of Asenapine in Adolescent Subjects With Schizophrenia

Status: Completed, Estimated PCD: 2013-03-10

Clinical trial

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Status: Active (not recruiting), Estimated PCD: 2022-10-25

Abstract

Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC.

Org: Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Memorial Sloan Kettering Cancer Center, Vall d’Hebron University Hospital/VHIO, Lausanne University Hospital, William Osler Health System,

Abstract

Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial.

Org: Copenhagen University Hospital, Washington University School of Medicine, ModernaTX, Rigshospitalet, Nordic Society of Gynaecologic Oncology–Clinical Trial Unit,

Abstract

Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma.

Org: University of Leicester and Leicester University Hospitals, University of Southampton, Harry Perkins Institute of Medical Research, Perth, Australia, Liverpool, United Kingdom,

Abstract

Randomized double-blind, placebo-controlled study of topical diclofenac in prevention of hand-foot syndrome in patients receiving capecitabine.

Org: All India Institute of Medical Sciences, Dr. Brairch, Abbisko Therapeutics, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, All India Institute of Medical Science (AIIMS),

Abstract

Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.

Org: Memorial Sloan Kettering Cancer Center, Niigata University Graduate School of Medical and Dental Sciences, ICON Research, Bristol Myers Squibb, West-German Cancer Center Essen,

Abstract

Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.

Org: Istituto Nazionale Tumori IRCCS Fondazione Pascale, Hospital Universitario Virgen Macarena, Maria Skłodowska-Curie National Institute of Oncology Center, Poznan University of Medical Sciences and Greater Poland Cancer Center, UPMC Hillman Cancer Center,

Abstract

Phase 3 randomized placebo-controlled trial of donepezil for late cancer-related cognitive impairment in breast cancer survivors exposed to chemotherapy from the Wake Forest NCORP Research Base REMEMBER trial (WF97116).

Org: Heartland NCORP, Minnesota Oncology Hematology PA - Coon Rapids, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Wake Forest University School of Medicine, Oncology Hematology Assoc of SW Indiana,

Abstract

Analysis of fruquintinib adverse events of special interest from phase 3 of the FRESCO-2 study.

Org: Vanderbilt-Ingram Cancer Center, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, University of Texas MD Anderson Cancer Center, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Veneto Institute of Oncology IOV - IRCCS,

Abstract

Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine.

Org: Institut Gustave Roussy, Hospital Universitario y Politecnico La Fe, ICO-Hospital Germans Trias i Pujol, Medical University of Gdansk, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,

Abstract

Subgroup analyses of safety and efficacy by number and types of prior lines of treatment in FRESCO-2, a global phase III study of fruquintinib in patients with refractory metastatic colorectal cancer.

Org: University of Texas MD Anderson Cancer Center, Veneto Institute of Oncology IOV - IRCCS, Hospital Universitario 12 de Octubre, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, National Cancer Center Hospital East, Kashiwa, Japan,

Abstract

Impact of geography on receipt of medical oncology consultation and neoadjuvant chemotherapy for triple negative and HER2 positive breast cancer.

Org: University of Toronto, Odette Cancer Centre, Sunnybrook Health Sciences Centre, ICES, Sunnybrook Odette Cancer Centre,

Abstract

Cost-effectiveness analysis of later-line therapies for metastatic colorectal cancer (mCRC) based on a novel methodology of network meta-analysis (NMA) of survival curves.

Org: The University of Arizona, Tucson, AZ, University of Arizona Cancer Center, University of Arizona, University of Arizona of Pharmacy, Department of Pharmacy Practice and Science,

Abstract

Pembrolizumab vs placebo for early-stage non‒small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS/KEYNOTE-091 study.

Org: North Estonia Medical Centre Foundation, The Catholic University of Korea, Hiroshima University Hospital, Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeylandów, Medical Oncology 2, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy,

Abstract

Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance.

Org: Kliniken Essen-Mitte, Agomab Spain, Centre Jean Perrin, GINECO-Centre Jean Perrin, Clermont-Ferrand, France, Istituto Tumori Milano + Fondazione Policlinico Universitario A. Gemelli IRCCS,

Abstract

Impact of nirogacestat on pain, a key symptom in patients with desmoid tumors (DT): Results from the phase 3 DeFi study.

Org: IQVIA Inc., Bratislava, Slovakia, IQVIA, Amsterdam, Netherlands, SpringWorks Therapeutics, Universität Heidelberg, Mannheim Cancer Center (MCC),

Abstract

Efficacy and safety of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer who had measurable residual disease: A post-hoc subgroup analysis of the PRIME study.

Org: Qilu Hospital of Shandong University, Jinan, China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China,

Abstract

Nationwide phase II randomized controlled trial of low-dose ibuprofen vs placebo for cancer-related cognitive impairment (CRCI).

Org: University of Rochester Medical Center, Wilmot Cancer Institute, Rochester, NY, University of Rochester Medical School, AdventHealth Orlando,

Abstract

Prevention of chemotherapy-induced neutropenia (CIN) with plinabulin (Plin) vs placebo (Plac) in patients (pts) with non-small cell lung cancer (NSCLC) treated with docetaxel (Doc): A pooled analysis from 3 randomized trials.

Org: Stanford Cancer Institute, Stanford, CA, BeyondSpring Pharmaceuticals, Inc., New York, NY, Newyork, NY,

Product

Placebo + Dabrafenib + Trametinib

Product

Placebo + Chemotherapy

Product

Placebo + Methotrexate

Product

Placebo plus platinum-based chemotherapy

Product

Docetaxel + Placebo

Product

Avelumab + Placebo

Product

TMZ-based radiochemotherapy with placebo

Product

placebo and abiraterone

Product

placebo + ADT + docetaxel

Product

Placebo + Androgen Deprivation Therapy

Abstract

BRCA1 and RAD51 methylation impact on outcome in patients with advanced ovarian cancer: A PAOLA-1 ancillary study.

Org: APHP-INSERM U1149 Universite Paris Diderot, European Georges Pompidou Hospital, Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Université,

Product

gefitinib + placebo

Product

Placebo + platinum-based chemotherapy

Product

Placebo + FOLFIRI

Product

Placebo + AVONEX

Product

NAC followed by adjuvant nivolumab

Product

Placebo and Bevacizumab